Itch relief showdown: which drug stops water-induced agony?

NCT ID NCT03808805

Completed Symptom relief Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two oral medications, aprepitant and hydroxyzine, to see which better reduces severe itching triggered by water contact in people with myeloproliferative neoplasms (a type of blood cancer). 63 participants who had persistent itching rated 5 or higher on a 10-point scale were randomly assigned to one of the drugs. The goal was to lower itching to 3 or below on the same scale.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AQUAGENIC PRURITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera aquagenic pruritus essential thrombocythemia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AQUAGENIC PRURITUS MYELOPROLIFERATIVE DISORDER

Contacts and locations

Locations

CHRU de Brest - Hôpital Morvan

Brest, Brest Cedex, 29609, France
CHU Grenoble Alpes

Grenoble, 38043, France
CHU d'Angers

Angers, 49933, France
CHU de Caen

Caen, 14033, France
CHU de Nantes

Nantes, 44093, France
Centre Hospitalier de Cornouaille

Quimper, Quimper, 29107, France
Centre Hospitalier de Douarnenez

Douarnenez, 29171, France
Centre Hospitalier des Pays de Morlaix

Morlaix, 29672, France
Centre Léon Bérard

Lyon, 69373, France
Hôpital Pontchaillou

Rennes, France
Hôpital Yves Le Foll

Saint-Brieuc, 22027, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.